Reimbursement of Trodelvy® for the treatment of inoperable or metastatic triple-negative breast cancer

Last week, the pharmaceutical company Gilead Sciences announced that Trodelvy® is reimbursed in Belgium as of the first of January 2023 for the treatment of adult patients with inoperable or metastatic triple-negative breast cancer. Patients must have received at least two prior lines of systemic (whole body) therapy, including at least one prior line of therapy for advanced disease. 

Triple-negative breast cancer is an aggressive form of breast cancer that often grows rapidly and spreads faster than other forms of breast cancer. Each year, more than 1,000 patients in Belgium are diagnosed with triple-negative breast cancer*, which mainly affects young women. Due to the absence of hormone receptors or overexpression of the HER-2 protein**, treatment options are limited for these patients. A study has shown that Trodelvy® can significantly increase survival in certain cases. An important step in the fight against breast cancer.

* Belgian Cancer Registry, facts and figures 2019
** HER2: Human Epidermal growth factor Receptor 2

Please find the link to the approved full summary of the product characteristics
Read the full publication on the website of the RIZIV/INAMI